Liminal BioSciences Provides R&D Update : vimarsana.com

/PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), announced today that the Company has nominated a lead...

Related Keywords

United Kingdom , Cambridge , Cambridgeshire , Canada , Fairhaven , Newfoundland , Bruce Pritchard , Liminal Biosciences Inc , Fairhaven Pharmaceuticals Inc , World Health Organisation , Agonist Development Program , Nasdaq , Antagonist Development Program , Market Watch Research , Chief Executive Officer , Watch Research , Future Market Insights , Gary Bridger , Interim Chief Scientific Officer , Study Results ,